Tempus AI (TEM) Investor Day 2026 summary

Strategic vision and platform evolution

• Focused on leveraging AI and multimodal data to transform diagnostics, drug discovery, and patient care, with a proprietary ecosystem integrating diagnostics, data, and applications.

• Embedded EHR integrations and agentic tools streamline clinical workflows and trial matching, enhancing provider and patient experiences.

• Foundation models and agentic workflows are being developed in partnership with leading pharma companies to deliver predictive insights and accelerate drug development.

• Expansion into rare disease and hereditary testing, including whole genome sequencing, aims to address unmet diagnostic needs and fuel growth.

• AI-driven applications are positioned to become reimbursable diagnostic tools, further differentiating the platform.

Diagnostics business performance and outlook

• Achieved 28% volume growth in Q1 2026, driven by oncology momentum and expanded hereditary cancer screening capabilities.

• Oncology ASPs expected to rise significantly, with reimbursement improvements and migration to FDA-approved xT CDx assays.

• Projecting $1.9B in annual diagnostics revenue by 2028, representing a 25% three-year CAGR.

• Comprehensive MRD portfolio and AI-enabled concurrent testing are expanding clinical utility and market share.

• Hereditary testing growth is normalizing, with mid-teens trajectory and long-term expansion into broader populations.

Data & applications business performance and outlook

• Data & Applications revenue reached $87M in Q1 2026, with 41% YoY growth and strong expansion of strategic partnerships.

• Over $2B in contracts signed to date, with $1.1B+ in total remaining contract value as of year-end 2025.

• Projecting at least $650M in annual Data revenue by 2028, with a 25%+ three-year CAGR.

• Foundation models and agentic platforms are driving new business models, including AI model deployment across pharma pipelines.

• Strategic partnerships with top pharma and biotech companies are expanding, diversifying revenue and embedding Tempus solutions across portfolios.